PrognosDx Health
Pioneering the future of cancer diagnostics through advanced epigenetic testing and innovative histone biomarkers.
Pioneering the future of cancer diagnostics through advanced epigenetic testing and innovative histone biomarkers.
PrognosDx Health is a biotechnology company that is pioneering the future of cancer diagnostics through advanced epigenetic testing and innovative histone biomarkers. Specializing in developing and commercializing epigenetic tests focusing on histone modification patterns, the company offers services such as pharmaceutical research-clinical sample analysis, clinical patient sample analysis tests for various cancers, and prostate cancer patient prognosis tests. Its products are instrumental in creating cancer prognostic assays, therapeutic response prediction assays, and research tools and reagents. The company's tissue-based global cellular histone biomarkers provide prognostic insights for several cancers, including prostate, pancreatic, breast, bladder, kidney, gastric, colon, and lung cancer. Founded in 2008, PrognosDx Health, Inc. is headquartered in Palo Alto, California.
The most recent investment in PrognosDx Health, Inc. was a $10.00K Debt Financing investment at 17 May 2011.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Debt Financing | $10.00K | - | 17 May 2011 |
No recent news or press coverage available for PrognosDx Health.
We care about your data, and we'd love to use cookies make your experience better.
